Efficacy of 3,4,3-LIHOPO for reducing neptunium retention in the rat after simulated wound contamination.
OBJECTIVE
The ligand 3,4,3-Li(1,2-HOPO) was tested for Np removal after intramuscular injection of 237Np nitrate in rats.


METHODS
Two experiments were performed, one with simultaneous injection of neptunium and LIHOPO at dosages ranging from 3 to 200 micromol kg(-1) and the other with delayed administration of LIHOPO 30 micromol kg(-1) from 5 min to 30 min after Np injection.


RESULTS
The data obtained after simultaneous injections showed that the ligand dosage effectiveness was not linear and depended on the tissues being considered. For bones, the best results were obtained with 200 micromol kg(-1) LIHOPO, where retention was reduced to 11% of controls. Maximum efficacies for removal in liver and kidney were obtained with 30 micromol kg(-1) LIHOPO, where retention was reduced to 39% and 1.6% of controls, respectively. At higher dosages, LIHOPO seemed to have a reverse effect on these tissues, demonstrated by a significant accumulation of the radionuclide. The delayed administration of LIHOPO dramatically decreased its efficacy. When administered 5 min after Np, LIHOPO was still efficient (60%, 37%, 7% of controls in bone, liver, kidneys, respectively) but not when treatment was delayed to 30 min.


CONCLUSIONS
These results demonstrated that LIHOPO was able to complex Np at the wound site but not after translocation to blood.
Paquet
F
F
Institut de Protection et de Sûreté Nucléaire, Département de Protection de la Santé de l'Homme et de Dosimétrie, Fontenay aux Roses, France. Francois.Paquet@ipsn.fr
Montègue
B
B
Ansoborlo
E
E
Hengé-Napoli
M H
MH
Houpert
P
P
Durbin
P W
PW
Raymond
K N
KN
D000818:Animals; D001372:Aza Compounds / Q000494:pharmacology*; D001842:Bone and Bones / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology*; D005260:Female; D007273:Injections, Intramuscular; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D009405:Neptunium / Q000378:metabolism* / Q000494:pharmacology; D011728:Pyridones / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D001372:Aza Compounds; D002614:Chelating Agents; D011728:Pyridones; C076998:N,N',N'',N'''-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane; D009405:Neptunium